NCT02943447View on ClinicalTrials.gov

Study to Evaluate the Safety, Tolerability, and Efficacy of Cilofexor in Adults With Primary Biliary Cholangitis Without Cirrhosis

PHASE2TerminatedINTERVENTIONAL

Enrollment

71

Participants

Timeline

Start Date

December 1, 2016

Primary Completion Date

September 4, 2019

Study Completion Date

September 4, 2019

Conditions

Primary Biliary Cholangitis

Interventions

DRUG

Cilofexor

Tablet(s) administered orally once daily, with food

DRUG

Placebo to match cilofexor

Tablet(s) administered orally once daily, with food

Trial Locations (25)

1090

Vienna

8036

Graz

22908

Charlottesville

23602

Newport News

30060

Marietta

33136

Miami

34211

Lakewood Rch

55114

Saint Paul

75203

Dallas

75246

Dallas

76012

Arlington

77030

Houston

80045

Aurora

95817

Sacramento

98104

Seattle

T2N 4Z6

Calgary

V5Z 1M9

Vancouver

V6Z 2K5

Vancouver

R3E 0T6

Winnipeg

M5G 2C4

Toronto

L4L 4Y7

Vaughan

B215 2GW

Birmingham

NW3 2QG

London

SE5 9RS

London

NR4 7UY

Norwich

Sponsors

Lead Sponsor

Gilead Sciences

All Listed Sponsors

lead

Gilead Sciences

INDUSTRY

NCT02943447 - Study to Evaluate the Safety, Tolerability, and Efficacy of Cilofexor in Adults With Primary Biliary Cholangitis Without Cirrhosis | Biotech Hunter | Biotech Hunter